Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

The Odyssee Study: Prevention of Dysbiosis Complications with Autologous Fecal Microbiota Transfer (FMT) in Acute Myeloid Leukemia (AML) Patients Undergoing Intensive Treatment: Results of a Prospective Multicenter Trial

Blood (2018) 132 (Supplement 1): 1444.

https://doi.org/10.1182/blood-2018-99-112825

Published: 2018

Journal Articles

Outcomes Following Hematopoietic Stem Cell Transplantation in Patients Treated with Chemotherapy with or without Gemtuzumab Ozogamicin for Acute Myeloid Leukemia

Cécile Pautas, Emmanuel Raffoux, MD, Juliette Lambert, Ollivier Legrand, MD PhD, Rebecca J Benner, Erik R. Vandendries, MD PhD, Karïn Gogat, Hervé Dombret, MD, Sylvie Castaigne, MD

Blood (2018) 132 (Supplement 1): 28.

https://doi.org/10.1182/blood-2018-99-111251

Published: 2018

Journal Articles

Fractionated Gemtuzumab Ozogamicin in Association with High Dose Chemotherapy: A Bridge to Allogeneic Stem Cell Transplantation in Refractory and Relapsed Acute Myeloid Leukemia?

Pierre-Edouard Debureaux, Myriam Labopin, MD PhD, Simona Lapusan, MD, Francoise Isnard, PhD, Rosa Adaeva, Agnès Bonnin, Pierre Hirsch, MDPhD, Francois Delhommeau, MD PhD, Giorgia Battipaglia, MD, Remy Duléry, MD, Federica Giannotti, MD, Florent Malard, MDPhD, Annalisa Ruggeri, MD, Anne Vekhoff, Ollivier Legrand, MD PhD, Mohamad Mohty, MD PhD, Eolia Brissot, MDPhD

Blood (2017) 130 (Supplement 1): 4603.

https://doi.org/10.1182/blood.V130.Suppl_1.4603.4603

Published: 2017

Journal Articles

Prevention of Dysbiosis Complications with Autologous Fecal Microbiota Transplantation (auto-FMT) in Acute Myeloid Leukemia (AML) Patients Undergoing Intensive Treatment (ODYSSEE study): First Results of a Prospective Multicenter Trial

Mohamad Mohty, MD PhD, Florent Malard, MDPhD, Evelyne D'Incan, MD, Xavier Thomas, MD, Christian Recher, MD PhD, Anne-Sophie Michallet, MD PhD, Pierre Peterlin, MD, Anne Vekhoff, Norbert Vey, Emilie Plantamura, Philippe Lehert, Joel Doré, Ollivier Legrand, MD PhD

Blood (2017) 130 (Supplement 1): 2624.

https://doi.org/10.1182/blood.V130.Suppl_1.2624.2624

Published: 2017

Journal Articles

Clono-Specific Evaluation of Minimal Residual Disease in Acute Myeloid Leukemia

Pierre Hirsch, Ruoping Tang, Nassera Abermil, Pascale Flandrin, Hannah Moatti, Mohamad Mohty, MD PhD, Ollivier Legrand, MD PhD, Luc Douay, MD PhD, Chrystele bilhou Nabera, Francois Delhommeau

Blood (2016) 128 (22): 1208.

https://doi.org/10.1182/blood.V128.22.1208.1208

Published: 2016

Journal Articles

Efficacy and Feasibility of Sorafenib As a Maintenance Agent after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia

Blood (2016) 128 (22): 4624.

https://doi.org/10.1182/blood.V128.22.4624.4624

Published: 2016

Journal Articles

Texture Analysis on Computed Tomography Predicts the Outcome of Patients with Hodgkin Lymphoma

Remy Dulery, MD, Anthony Dohan, MD, Maxime Barat, Mor Seny Gueye, Catherine Phan, MD, Zora Marjanovic, MD, Malek Aoudjhane, MD, Elise Corre, MD, Marie-Paule Lemonnier, MD, Anne Vekhoff, MD, Laurent Garderet, MD PhD, Ollivier Legrand, MD PhD, Paul Coppo, MD PhD, Philippe Soyer, MD PhD, Caroline Reinhold, MD, Lionel Arrivé, MD PhD, Benoit Gallix, MD PhD, Mohamad Mohty, MD PhD

Blood (2016) 128 (22): 1832.

https://doi.org/10.1182/blood.V128.22.1832.1832

Published: 2016

Journal Articles

Targeting Acute Myeloid Leukemia with a New CXCR4 Antagonist IgG1 Antibody (PF-06747143)in NOD/SCID Mice

Yanyan Zhang, PhD, Erika Saavedra, MD, Ruoping Tang, Shu-Hui Liu, Tod Smeal, Valeria Fantin, PhD, Stephane De Botton, MD PhD, Ollivier Legrand, MD PhD, William Vainchenker, MD PhD, Flavia Pernasetti, Fawzia Louache, PhD

Blood (2015) 126 (23): 1362.

https://doi.org/10.1182/blood.V126.23.1362.1362

Published: 2015

Journal Articles

Differential Association of Calreticulin Type 1 and Type 2 Mutations with Myelofibrosis and Essential Thrombocytemia: Relevance for Disease Evolution

Blood (2014) 124 (21): 1823.

https://doi.org/10.1182/blood.V124.21.1823.1823

Published: 2014

Journal Articles

Impact of FLT3-ITD Mutational Burden in 469 Acute Myeloid Leukemia (AML) Patients

Pierre Hirsch, MD, Myriam Labopin, Christophe Marzac, MD, Anne-Claire Mamez, MD, Ruoping Tang, Françoise Isnard, MD, Simona Lapusan, Anne Vekhoff, MD, Norbert C Gorin, MD, Jean-Pierre Marie, Mohamad Mohty, Ollivier Legrand, MD PhD

Blood (2014) 124 (21): 1033.

https://doi.org/10.1182/blood.V124.21.1033.1033

Published: 2014

Journal Articles

Prognostic Impact Of Body Mass Index (BMI) In Acute Myeloid Leukemia (AML)

Emmanuelle Kempf, Pierre Hirsch, Myriam Labopin, Christophe Marzac, MD, Jean-Yves Perrot, Françoise Isnard, MD, Jean-Pierre Marie, MD, Mohamad Mohty, MD, PhD, Ollivier Legrand, MD, PhD

Blood (2013) 122 (21): 2658.

https://doi.org/10.1182/blood.V122.21.2658.2658

Published: 2013

Journal Articles

Two Years Follow-up Results of Graspall/Graall-SA2–2008 Study: L-Asparaginase-Loaded Red Blood Cell Combined with Standard EWALL Chemotherapy in Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (Ph-ALL)

Blood (2012) 120 (21): 1473.

https://doi.org/10.1182/blood.V120.21.1473.1473

Published: 2012

Journal Articles

Clinical Implications for Patients with Low JAK2V617F Allele Burden

Marguerite Vignon, Dorota Jeziorowska, Pierre Hirsch, MD, Ollivier Legrand, MD, PhD, Nicole Casadevall, MD, Francois Delhommeau, PharmD, PHD, Christophe Marzac, MD

Blood (2012) 120 (21): 1745.

https://doi.org/10.1182/blood.V120.21.1745.1745

Published: 2012

Journal Articles

Molecular Minimal Residual Disease After Induction Is Related to ABC Proteins' Activity and Associated with Survival in 26 Patients with NPM1 Mutated Acute Myeloid Leukemia

Pierre Hirsch, Ruoping Tang, Christophe Marzac, MD, Fanny Fava, Jean-Yves Perrot, Françoise Isnard, MD, Jean-Pierre Marie, Ollivier Legrand, MD, PhD

Blood (2012) 120 (21): 4909.

https://doi.org/10.1182/blood.V120.21.4909.4909

Published: 2012

Journal Articles

High Id1 Expression Is Associated with Poor Prognosis in 237 Patients with Acute Myeloid Leukemia.

Pierre Hirsch, II, R. Tang, Simona Lapusan, Sr., Christophe Marzac, Sr., Jean-Pierre Marie, Ollivier Legrand, MD, PhD

Blood (2009) 114 (22): 4687.

https://doi.org/10.1182/blood.V114.22.4687.4687

Published: 2009

Journal Articles

Prognosis Value of Flt3 Internal Tandem Duplication and P-Glycoprotein Functionality, in 171 AML.

Christophe Marzac, MD, Irene Teyssandier, MD, Jean Yves Perrot, MD, Anne Marie Faussat, MD, Ruoping Tang, PhD, Nicole Casadevall, MD, PhD, Jean Pierre Marie, MD, PhD, Ollivier Legrand, MD, PhD

Blood (2005) 106 (11): 2375.

https://doi.org/10.1182/blood.V106.11.2375.2375

Published: 2005

NARROW

The Odyssee Study: Prevention of Dysbiosis Complications with Autologous Fecal Microbiota Transfer (FMT) in Acute Myeloid Leukemia (AML) Patients Undergoing Intensive Treatment: Results of a Prospective Multicenter Trial

Outcomes Following Hematopoietic Stem Cell Transplantation in Patients Treated with Chemotherapy with or without Gemtuzumab Ozogamicin for Acute Myeloid Leukemia

Fractionated Gemtuzumab Ozogamicin in Association with High Dose Chemotherapy: A Bridge to Allogeneic Stem Cell Transplantation in Refractory and Relapsed Acute Myeloid Leukemia?

Prevention of Dysbiosis Complications with Autologous Fecal Microbiota Transplantation (auto-FMT) in Acute Myeloid Leukemia (AML) Patients Undergoing Intensive Treatment (ODYSSEE study): First Results of a Prospective Multicenter Trial

Clono-Specific Evaluation of Minimal Residual Disease in Acute Myeloid Leukemia

Efficacy and Feasibility of Sorafenib As a Maintenance Agent after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia

Texture Analysis on Computed Tomography Predicts the Outcome of Patients with Hodgkin Lymphoma

Targeting Acute Myeloid Leukemia with a New CXCR4 Antagonist IgG1 Antibody (PF-06747143)in NOD/SCID Mice

Differential Association of Calreticulin Type 1 and Type 2 Mutations with Myelofibrosis and Essential Thrombocytemia: Relevance for Disease Evolution

Impact of FLT3-ITD Mutational Burden in 469 Acute Myeloid Leukemia (AML) Patients

Prognostic Impact Of Body Mass Index (BMI) In Acute Myeloid Leukemia (AML)

Two Years Follow-up Results of Graspall/Graall-SA2–2008 Study: L-Asparaginase-Loaded Red Blood Cell Combined with Standard EWALL Chemotherapy in Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (Ph-ALL)

Clinical Implications for Patients with Low JAK2V617F Allele Burden

Molecular Minimal Residual Disease After Induction Is Related to ABC Proteins' Activity and Associated with Survival in 26 Patients with NPM1 Mutated Acute Myeloid Leukemia

High Id1 Expression Is Associated with Poor Prognosis in 237 Patients with Acute Myeloid Leukemia.

Prognosis Value of Flt3 Internal Tandem Duplication and P-Glycoprotein Functionality, in 171 AML.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only